Research programme: NMDA receptor antagonists - Yaupon Therapeutics
Alternative Names: Analgesics - Yaupon Therapeutics; Norketamine; S-norketamine; YT 1006Latest Information Update: 12 Jan 2012
At a glance
- Originator Yaupon Therapeutics
- Developer Ceptaris Therapeutics
- Class Cyclohexanes
- Mechanism of Action NMDA receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Neuropathic pain
Most Recent Events
- 05 Jan 2012 Discontinued - Preclinical for Neuropathic pain in USA (PO)
- 02 Feb 2005 YT 1006 is available for licensing (http://www.yaupontherapeutics.com)
- 03 Nov 2004 Preclinical trials in Neuropathic pain in USA (unspecified route)